Hybio Pharmaceutical Co., Ltd. (300199.SZ)
CNY 14.06
(3.23%)
CNY 14.06
(3.23%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.53 Million | 15.8 Million | 156.82 Million | 47.99 Million | 104.63 Million | 46.99 Million |
| Net Income | -515.44 Million | -372.54 Million | 28.43 Million | -609.29 Million | -884.79 Million | -340.77 Million |
| Depreciation & Amortization | 155.54 Million | 140.59 Million | 135.77 Million | 104.54 Million | 101.32 Million | 96.62 Million |
| Deferred income taxes | -724.42 Thousand | -544.19 Thousand | 3.36 Million | 13.9 Million | -6.78 Million | -14.48 Million |
| Stock-based compensation | 3.22 Million | 17.24 Million | - | - | 24.34 Million | 12.62 Million |
| Change in working capital | 124.33 Million | -59.18 Million | 121.2 Million | 42.72 Million | 357.79 Million | -320.56 Million |
| Other non-cash items | 129.49 Million | 306.94 Million | -128.58 Million | 510.02 Million | 530.3 Million | 611.71 Million |
| Investing Cash Flow | 147.71 Million | 51.71 Million | -178.38 Million | -258.46 Million | -595.99 Million | -419.86 Million |
| Investments in PPE | -81.76 Million | -189.84 Million | -198.99 Million | -243.66 Million | -570.15 Million | -365.57 Million |
| Acquisitions | 1.07 Million | -100 Thousand | -3.91 Million | 243.71 Million | 570.2 Million | 371.02 Million |
| Investment purchases | -150 Thousand | -50 Million | -2.7 Million | -15 Million | -36.25 Million | -60 Million |
| Sales/Maturities of investments | 228.55 Million | 246.1 Million | 27.09 Million | 139.12 Thousand | 10.36 Million | 264 Thousand |
| Other Investing Activities | 229.47 Million | 45.55 Million | 136 Thousand | -243.66 Million | -570.15 Million | -365.57 Million |
| Financing Cash Flow | 95.84 Million | -71.1 Million | -253.66 Million | -71.67 Million | -425.19 Million | 654.58 Million |
| Debt repayment | -208.89 Million | -478.97 Million | -1.63 Billion | -725.87 Million | -572.96 Million | -724.12 Million |
| Dividends payments | -117.89 Million | -114.8 Million | -115.64 Million | -104.95 Million | -114.59 Million | -252.76 Million |
| Common Stock Repurchased | - | - | - | - | -413.24 Million | -105.9 Million |
| Common Stock Issuance | - | - | - | - | 413.24 Million | - |
| Other Financing Activities | 4.84 Million | 522.66 Million | 1.49 Billion | 759.15 Million | 262.36 Million | 1.63 Billion |
| Accounts receivables | 121.19 Million | -60.53 Million | 17.55 Million | 136.3 Million | 354.97 Million | -146.49 Million |
| Accounts payables | -17.12 Million | 59.6 Million | 80.99 Million | -65.11 Million | 2.8 Million | -139.18 Million |
| Inventory | 20.98 Million | -57.7 Million | 19.28 Million | -42.37 Million | 6.79 Million | -20.4 Million |
| Other working capital | -29.5 Thousand | -544.19 Thousand | 3.36 Million | 13.9 Million | -6.78 Million | -300.15 Million |
| Cash at beginning of period | 98.99 Million | 100.5 Million | 377.31 Million | 657.54 Million | 1.56 Billion | 1.26 Billion |
| Cash at end of period | 339.93 Million | 98.99 Million | 100.5 Million | 377.31 Million | 657.54 Million | 1.56 Billion |
| Capital Expenditure | -81.76 Million | -189.84 Million | -198.99 Million | -243.66 Million | -570.15 Million | -365.57 Million |
| Effect of forex changes on cash | 923.27 Thousand | 2.06 Million | -1.58 Million | 1.93 Million | 9.85 Million | 14.05 Million |
| Net cash flow / Change in cash | 240.94 Million | -1.51 Million | -276.8 Million | -280.22 Million | -906.7 Million | 295.77 Million |
| Free Cash Flow | -85.29 Million | -174.03 Million | -42.17 Million | -195.67 Million | -465.51 Million | -318.57 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -24.44 Million | 3.74 Million | -14.1 Million | -333.32 Million | -515.44 Million | -146.41 Million |
| Depreciation & Amortization | - | 32.74 Million | 32.74 Million | 155.54 Million | 155.54 Million | -75.21 Million |
| Deferred income taxes | - | - | - | - | -724.42 Thousand | -0.37 |
| Stock-based compensation | - | 4.77 Million | - | 3.22 Million | 3.22 Million | -20.72 Million |
| Change in working capital | - | -42.84 Million | - | 142.15 Million | 124.33 Million | 26.54 Million |
| Other non-cash items | 79.53 Million | 46.82 Million | 29.86 Million | 86.4 Million | 129.49 Million | 199.17 Million |
| Investing Cash Flow | -28.05 Million | 13.59 Million | -14.88 Million | -8.29 Million | 147.71 Million | 25.09 Million |
| Investments in PPE | -27.5 Million | -25.25 Million | -17.45 Million | -8.7 Million | -81.76 Million | -8.68 Million |
| Acquisitions | 100 Thousand | 42.85 Million | 2.56 Million | 408 Thousand | 1.07 Million | 520 Thousand |
| Investment purchases | -650 Thousand | -4 Million | - | - | -150 Thousand | - |
| Sales/Maturities of investments | - | - | 614.7 Thousand | - | 228.55 Million | 33.25 Million |
| Other Investing Activities | 100 Thousand | 41 Million | 1.04 Million | 408 Thousand | 229.47 Million | 519.99 Thousand |
| Financing Cash Flow | 40.75 Million | -5.45 Million | -301.14 Million | 247.12 Million | 95.84 Million | -40.71 Million |
| Debt repayment | -63.56 Million | -85.2 Million | -313.72 Million | -280.15 Million | -208.89 Million | -280.28 Million |
| Dividends payments | -26.89 Million | -20.73 Million | -28.47 Million | -41.19 Million | -117.89 Million | -30.34 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 4.08 Million | -89.74 Million | 12.58 Million | 8.16 Million | 4.84 Million | 269.91 Million |
| Accounts receivables | - | -6.18 Million | - | 121.19 Million | 121.19 Million | 41.49 Million |
| Accounts payables | - | - | - | - | -17.12 Million | - |
| Inventory | - | -41.42 Million | - | 20.98 Million | 20.98 Million | 5.77 Million |
| Other working capital | - | 4.77 Million | - | -29.5 Thousand | -29.5 Thousand | -20.72 Million |
| Cash at beginning of period | 67.53 Million | 45.29 Million | 339.93 Million | 49.99 Million | 98.99 Million | 82.26 Million |
| Cash at end of period | 135.42 Million | 73.82 Million | 45.29 Million | 339.93 Million | 339.93 Million | 49.99 Million |
| Capital Expenditure | -27.5 Million | -25.25 Million | -17.45 Million | -8.7 Million | -81.76 Million | -8.68 Million |
| Effect of forex changes on cash | 109.6 Thousand | 1.47 Million | 412.5 Thousand | 343.76 Thousand | 923.27 Thousand | -16.68 Thousand |
| Net cash flow / Change in cash | 67.89 Million | 28.53 Million | -294.63 Million | 289.94 Million | 240.94 Million | -32.27 Million |
| Free Cash Flow | 27.57 Million | -7.42 Million | -1.68 Million | 42.06 Million | -85.29 Million | -25.32 Million |
CING
SUH
9562
CXDO
MRM
KRG